• 2015-2016. Postdoctoral scientist, Department of Biological Sciences, KAIST
• 2016-2019. Postrdoctoral Fellow, Research Lab of Electronics, MIT
• 2019-Present. Senior Research Scientist, KIST
• 2021-Present. Associate Professor, UST

• Developing cancer immunotherapy and cancer metabolism drugs
• Identification of novel targets for cancer therapy leveraging CRISPR-Cas screens
• Elucidation of the mechanism of action of the novel therapeutic targets
• Cellular programming by genetic engineering and synthetic biology

Peer reviewed journals

1. Kim, T., Weinberg, BH., Wong W., and Lu, TK. (2021). Scalable recombinase-based gene expression cascades. Nat. Commun. 12: 2711.
2. Kim, T. and Lu, TK. (2019). CRISPR/Cas-based devices for mammalian synthetic biology. Curr. Opin. Chem. Biol. 52, 23-30.
3. Kim, T. and Lim, D.-S. (2016) The SRF-YAP-IL6 axis promotes breast cancer stemness. Cell Cycle. 15,1311-1312.
4. Kim, T.*, Hwang, D.*, Lee, D., Kim, J.-H., Kim, S.-Y., and Lim, D.-S. (2016). Myocardin-Related Transcription Factors (MRTF) potentiates TEAD-YAP transcriptional activity upon extracellular stimuli. EMBO J. 36(4), 520-535. *These authors contributed equally to this work.
5. Kim, T., Yang, S. –J., Hwang, D., Song, J., Kim, M., Kim, S. K., Kang, K., Ahn J., Lee, D., Kim, M. Y., Kim, S., Koo, J. S., Koh, S. S., Kim, S. –Y., and Lim, D. –S. (2015). A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat. Commun. 6: 10186.